Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.
Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.